Cardiac Adverse Events in Patients Receiving Immune Checkpoint Inhibitors in the Adjuvant Setting: An FDA Pooled Analysis
Annals of Noninvasive Electrocardiology · 2025
DOI: 10.1111/anec.70087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Noninvasive Electrocardiology, 2025. Verfasst von Asma Dilawari und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, Maryland, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Cardiotoxicity, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. By releasing blocks (checkpoints) on the immune system, they elicit powerful antitumor effects. Despite improving survival, ICIs are associated with serious cardiac toxicities. Previous reports have focused on advanced cancer; cardiotoxicity data are therefore limited in the curative setting. We evaluated ICI cardiotoxicity in the non‐metastatic setting, where long‐term cardiac safety is a growing public health concern.
Methods
ICIs approved in the adjuvant setting were pooled and trials with combination chemotherapy were excluded. Cardiac adverse events (AEs) and emerging cardio‐metabolic risks (hyperglycemia, weight gain, hypothyroidism) were assessed. The relative risk (RR) of cardiotoxicity was assessed.
Results
Ten randomized controlled trials of atezolizumab, ipilimumab, nivolumab, and pembrolizumab in multiple solid tumors were evaluated; among 9244 patients, 5338 received ICIs. No trial performed routine cardiac monitoring. Six percent of ICI patients vs. 4.6% in placebo (RR 1.24, 95% CI 1.04, 1.49) had a cardiac AE and 13 (0.2%) of ICI patients experienced a fatal cardiac AE (RR 4.76, 95% CI 1.07, 21.06). Older age and male sex were associated with a higher risk for cardiac fatality. Arrhythmia was the most common cardiac AE; hypothyroidism was more frequent (14% vs. 2.5%) among ICI‐treated patients.
Conclusion
This is the largest pooled analysis of cardiac AEs associated with ICIs in the adjuvant setting. Despite no formalized testing for subclinical cardiotoxicity, ICI treatment increased cardiac AEs. These findings are relevant for long‐term cancer survivors, clinicians, and particularly in new drug development, where cardiotoxicity may be substantially underestimated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
- Oncology Center of Excellence (OCE), U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
ORCID-Profile: Mori J Krantz, Ilynn Bulatao
Zitieren
APA
Dilawari, A., Krantz, M. J., Bulatao, I., Joeng, H. K., Neilson, M., Wedam, S., Gao, X., Fiero, M. H., Nair, A., Theoret, M., & Amiri-Kordestani, L. (2025). Cardiac Adverse Events in Patients Receiving Immune Checkpoint Inhibitors in the Adjuvant Setting: An FDA Pooled Analysis. Annals of Noninvasive Electrocardiology. https://doi.org/10.1111/anec.70087
Vancouver
Dilawari A, Krantz MJ, Bulatao I, Joeng HK, Neilson M, Wedam S, et al. Cardiac Adverse Events in Patients Receiving Immune Checkpoint Inhibitors in the Adjuvant Setting: An FDA Pooled Analysis. Annals of Noninvasive Electrocardiology. 2025. doi:10.1111/anec.70087
BibTeX
@article{Dilawari2025,
author = {Dilawari, Asma and Krantz, Mori J and Bulatao, Ilynn and Joeng, Hee-Koung and Neilson, Marc and Wedam, Suparna and Gao, Xin and Fiero, Mallorie H and Nair, Abhilasha and Theoret, Marc and Amiri-Kordestani, Laleh},
title = {Cardiac Adverse Events in Patients Receiving Immune Checkpoint Inhibitors in the Adjuvant Setting: An FDA Pooled Analysis},
journal = {Annals of Noninvasive Electrocardiology},
year = {2025},
doi = {10.1111/anec.70087}
}
EUVIMED